News

Throughout the pandemic, rheumatologists have been concerned that their patients may be at risk of developing more severe forms of the COVID-19 disease as a result of their rheumatic disease or treatment.

“This class of medication provides an alternative therapeutic option for those that have an inadequate response to conventional DMARDs or biologic therapy.”

People with rheumatoid arthritis are at increased risk of osteoporosis. Test your knowledge of how the risk of osteoporosis can be minimized in these patients.

Kim Bennell, PhD, discusses her study “Effectiveness of an Unsupervised Online Yoga Program on Pain and Function in People With Knee Osteoarthritis: A Randomized Clinical Trial.”

Although results are promising, findings should be interpreted with caution, as the study was underpowered and terminated early due to the COVID-19 pandemic.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 24, 2022.

Bonnie L Bermas, MD, discusses the ways in which the Supreme Court decision to overturn Roe v Wade will change the way rheumatologists are able to care for their patients.

Although results were associative rather than causative, a decrease in BMI may prevent, delay, or slow the structural defects in knee osteoarthritis.

"Dactylitis is considered a core domain of musculoskeletal symptoms in psoriatic arthritis and is important for both patients and physicians when developing treatment strategies.”

The FDA approved risankizumab in June for adult patients with Crohn’s disease, representing the first IL-23 treatment to be approved for this patient population.

Fatigue, a highly multifactorial manifestation of lupus, can be related to disease activity or independent of the disease itself. Investigators determined whether fatigue could be a significant confounder of Physician Global Assessment ratings.

Despite worldwide trend data, incidence trends for dermatomyositis do not show increases among the study population.

"Online interventions have the potential to reach a wide audience, allowing exercise to be undertaken from the comfort and convenience of home and thereby overcoming some of the barriers to exercise reported in the osteoarthritis population.”

Rebecca Shepherd, MD, MBA, FACR, FACP, discusses the American College of Rheumatology's 2022 Rheumatic Disease Report Card in depth, including what can be done to improve scores and the next steps for her team.

CLEC2B, a key gene linked to ferroptosis regulators in psoriatic arthritis, is differentially expressed in a variety of cancers and is associated with immune cell infiltration as well as immune checkpoints.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 17, 2022.

The guidelines will provide more options for the treatment and prevention of glucocorticoid-induced osteoporosis and will inform rheumatologists about the requirements for anti-resorptive therapy after anabolic agents are discontinued.

Bimekizumab provided maintenance of completely clear skin and health-related quality of life in most patients with moderate-to-severe plaque psoriasis over a 3-year period.

Results were based on the phase 4 MIRROR trial, which analyzed differences in treatment response for concomitant therapy compared with placebo in adults with uncontrolled gout.

The effect of sleep health on disease prevention may have a profound impact on women when it comes to systemic lupus erythematosus (SLE).

For the second annual Interstitial Lung Disease Day, Dr. Briana DiSilvio expands on the background of ILDs and the latest care practices.

The updated guidelines highlight new recommendations for medications, flexibility in drug selection, and sequential therapy.

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, frequently co-occurs with the immune-mediated inflammatory condition, psoriasis.

Investigators believe that coronary intervention, intensified medical therapy, and an aggressive risk factor optimization approach should be available to patients with rheumatic disease presenting with myocardial infarction whenever possible.

New mothers are understandably nervous about taking medication while breastfeeding. Which treatments are appropriate for breastfeeding women with rheumatoid arthritis? Test your knowledge with this quiz.

In this Q&A, Tamara van Hal, MD, discussed the findings of her study that evaluated the extent of work and activity impairment in patients with psoriatic arthritis and examined determinants associated with this impairment.

In SLE, higher doses of prednisolone and the use of immunosuppressive agents, such as cyclophosphamide, have been associated with higher rates of infective sequelae.

A study presented at ASBMR 2022 leveraging data from more than a dozen countries details trends in hip fracture incidence and projects potential incidence increases by 2050.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 10, 2022.

The Lupus Research Alliance's 2022 Global Team Science Awards (GTSA) grant will provide $3 million for 3 years to each of the winners.